Medical Scientist Training Program    Back to Main

Faculty Detail    
Campus Address WTI 630 Zip 3300
Phone  (205) 934-7077
Other websites

Undergraduate  Carnegie Institute of Technology    1967  B.S. 
Graduate  University of Rochester    1970  M.S. 
Graduate  University of Rochester    1972  Ph.D. 

Faculty Appointment(s)
Appointment Type Department Division Rank
Secondary  Pharmacology/Toxicology   Pharmacology/Toxicology Chair's Office Associate Professor
Center  Comp Arthritis, MSK, Bone & Autoimmunity Ctr  Comp Arthritis, MSK, Bone & Autoimmunity Ctr Professor
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Professor
Center  Ctr for Glial Bio in Med  Ctr for Glial Bio in Med Professor
Primary  Radiation Oncology   Rad Onc - Radiobiology Professor
Secondary  Surgery   Surgery - General Surgery Professor
Secondary  Pathology   Pathology Chair Office Professor

Graduate Biomedical Sciences Affiliations
Biochemistry and Molecular Genetics Program 
Integrative Biomedical Sciences 
Medical Scientist Training Program 
Pathobiology and Molecular Medicine 

Biographical Sketch 
Dr. Donald J. Buchsbaum was born in New York City in March 1945. In 1972 he received his Ph.D. in Biophysics-Immunology from the University of Rochester. Before coming to UAB in 1990, he was an Assistant Professor at the University of Michigan and the University of Minnesota.

Society Memberships
Organization Name Position Held Org Link
American Association for Cancer Research 
American Society for Therapeutic Radiation Oncology 
American Society of Clinical Oncology 

Research/Clinical Interest
Cancer immunotherapy
My research is focused on the use of monoclonal antibodies that bind cancer cell surface receptors for cancer therapy in combination with chemotherapy agents, Wnt inhibitors, or radiation. This research involves investigation of the mechanisms of enhanced cytotoxicity produced by combination treatment. Orthotopic and metastatic breast, ovarian, and pancreatic cancer xenograft models are being used to optimize therapeutic regimens in collaboration with investigators from the Divisions of Gynecologic Oncology and Hematology/Oncology at UAB. We are also investigating the use of small molecule inhibitors of the Wnt pathway produced at Southern Research for cancer therapy and targeting of cancer initiating cells in breast, ovarian, and pancreatic cancer models. Other research involves cancer treatment with alpha-particle emitters conjugated to monoclonal antibodies. In collaboration with investigators at HudsonAlpha Institute for Biotechnology, we are investigating the use of genomics to predict the response of patients with triple-negative breast cancer, ovarian cancer, or pancreatic cancer treated with chemotherapy. Recent efforts involve the use of histone deacetylase inhibitors to upregulate the MHCII pathway and immune response against syngeneic breast and ovarian cancer models, which is being investigated in combination with checkpoint inhibitor therapy.

Selected Publications 
Publication PUBMEDID
Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S, Carpenter M, LoBuglio AF: Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 9:3731-3741, 2003.  14506165 
Oh S, Stish BJ, Vickers SM, Buchsbaum DJ, Saluja AK, Vallera DA: A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer. Pancreas 39:913-922, 2010.  20182395 
Kim H, Folks KD, Guo L, Stockard CR, Fineberg NS, Grizzle WE, George JF, Buchsbaum DJ, Morgan DE, Zinn KR: DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy. Mol Imaging Biol 13:94-103, 2011  20383593 
Arnoletti JP, Frolov A, Eloubeidi M, Keene K, Posey J, Wood T, Greeno E, Jhala N, Varadarajulu S, Russo S, Christein J, Oster R, Buchsbaum DJ, Vickers SM: A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer. Cancer Chemother Pharmacol 67: 891-897, 2011.  20589377 
McNally LR, Welch DR, Beck BH, Stafford LJ, Long JW, Sellers JC, Huang Z-Q, Grizzle WE, Stockard CR, Nash KT, Buchsbaum DJ: KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model. Clin Exp Metastasis 27:591-600, 2010.  20844932 
Bevis KS, McNally LR, Sellers JC, Della Manna D, Londoño Joshi AI, Amm H, Straughn JM, Jr, Buchsbaum DJ: Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. Gynecol Oncol, 121:193-199, 2011.  21211830 
Kim H, Folks KD, Guo L, Sellers JC, Fineberg NS, Stockard CR, Grizzle WE, Buchsbaum DJ, Morgan DE, George JF, Zinn KR: Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging. Mol Imaging 10:153-167, 2011.  21496446 
Oh S, Todhunter DA, Panoskaltsis-Mortari A, Buchsbaum DJ, Vallera DA: A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse model of orthotopic neoplasm. Pancreas 41:789-796, 2012.   22258068 
Lin C, Lu W, Zhang W, Londoño-Joshi AI, Buchsbaum DJ, Bu G, Li Y: The C-terminal region Mesd peptide mimics full-length Mesd and acts as an inhibitor of Wnt/beta-catenin signaling in cancer cells. PLoS ONE 8:e58102, 2013.   23469146 
Kerr EH, Frederick PJ, Egger ME, Stockard CR, Sellers J, DellaManna D, Oelschlager DK, Amm HM, Eltoum IE, Straughn JM, Buchsbaum DJ, Grizzle WE, McNally LR: Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma. Ann Surg Oncol 20: 3059-3065, 2013.  23525731 
Devine DJ, Rostas JW, Metge BJ, Das S, Mulekar MS, Tucker JA, Grizzle WE, Buchsbaum DJ, Shevde LA, Samant RS: Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-ß/SMAD signaling. Oncogene 33:2620-2628, 2014.  23770854 
Kim H, Rigell CJ, Zhai G, Lee SK, Samuel SL, Martin A, Umphrey HR, Stockard CR, Beasley TM, Buchsbaum DJ, Li LS, Boothman DA, Zinn KR: Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers. Mol Imaging Biol 16:85-94, 2014.  23836505 
Bey EA, Reinicke KE, Srougi MC, Varnes M, Anderson VE, Pink JJ, Li LS, Patel M, Cao L, Moore Z, Rommel A, Boatman M, Lewis C, Euhus DM, Bornmann WG, Buchsbaum DJ, Spitz DR, Gao J, Boothman DA: Catalase abrogates beta-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers. Mol Cancer Ther 12:2110-2120, 2013.  23883585 
Arend RC, Londoño-Joshi AI, Straughn JM Jr, Buchsbaum DJ: The Wnt/β-catenin pathway in ovarian cancer: a review. Gynecol Oncol 131:772-779, 2013.  24125749 
Fauci JM, Sabbatino F, Wang Y, Londoño-Joshi AI, Straughn JM Jr, Landen CN, Ferrone S, Buchsbaum DJ: Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. Gynecol Oncol 132:203-210, 2014.  24216048 
Londoño-Joshi AI, Arend RC, Aristizibal L, Lu W, Samant RS, Metge MJ, Hidalgo B, Grizzle WE, Conner M, Forero-Torres A, LoBuglio AF, Li Y, Buchsbaum DJ: Effect of niclosamide on basal-like breast cancers. Mol Cancer Ther 13:800-811, 2014.   24552774 
Li Y, Li PK, Roberts MJ, Arend RC, Samant RS, Buchsbaum DJ: Multi-targeted therapy of cancer by niclosamide: a new application for an old drug. Cancer Lett 349:8-14, 2014.  24732808 
Arend RC, Londoño-Joshi AI, Samant RS, Li Y, Conner M, Hidalgo B, Alvarez RD, Landen CN, Straughn JM, Buchsbaum DJ: Inhibition of Wnt/ß-catenin pathway by niclosamide: A therapeutic target for ovarian cancer. Gynecol Oncol 134:112-120, 2014  24736023 
Kaliberov SA, Kaliberova LN, Buchsbaum DJ, Curiel DT: Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus. Cancer Gene Ther 204:264-274, 2014.  24903014 
Varley KE, Gertz J, Roberts BS, Davis NS, Bowling KM, Kirby MK, Nesmith AS, Oliver PG, Grizzle WE, Forero-Torres A, Buchsbaum DJ, LoBuglio AF, Myers RM: Recurrent read-through fusion transcripts in breast cancer. Breast Cancer Res Treat 146:287-297, 2014.  24929677 
Kim H, Samuel SL, Zhai G, Rana S, Taylor M, Umphrey HR, Oelschlager DK, Buchsbaum DJ, Zinn KR: Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer. Cancer Biol Ther 15:1053-1060, 2014.  25084100 
Walters Haygood CL, Arend RC, Straughn JM, Buchsbaum DJ: Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival? World J Stem Cells 6:441-447, 2014.  25258665 
Che P, Yang Y, Han X, Hu M, Sellers JC, Londono-Joshi AI, Cai GQ, Buchsbaum DJ, Christein JD, Tang Q, Chen D, Li Q, Grizzle WE, Lu YY, Ding Q: S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase. Sci Rep 5:8453, 2015.  25677816 
Kim H, Buchsbaum DJ, Zinn KR: A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of TRA-8/DR5 Oligomers Predicts TRA-8 Therapeutic Efficacy in Breast and Pancreatic Cancer Mouse Models. Mol Imaging Biol 18:325-333, 2016.  26552657 
Boone JD, Arend RC, Johnston BE, Cooper SJ, Gilchrist SA, Oelschlager DK, Grizzle WE, McGwin G Jr, Gangrade A, Straughn JM Jr, Buchsbaum DJ: Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974. Lab Invest 96:249-59, 2016.  26658453 
Morrow KA, Das S, Meng E, Menezes ME, Bailey SK, Metge BJ, Buchsbaum DJ, Samant RS, Shevde LA: Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer. Oncotarget 7:17991-8005, 2016.  26908451 
Forero A, Li Y, Chen D, Grizzle WE, Updike KL, Merz ND, Downs-Kelly E, Burwell TC, Vaklavas C, Buchsbaum DJ, Myers RM, LoBuglio AF, Varley KE: Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes.
Cancer Immunol Res 4:390-399, 2016.  
Fancy RM, Wang L, Schmid T, Zeng Q, Wang H, Zhou T, Buchsbaum DJ, Song Y: Characterization of the Interactions between Calmodulin and Death Receptor 5 in Triple-negative and Estrogen Receptor-positive Breast Cancer Cells: AN INTEGRATED EXPERIMENTAL AND COMPUTATIONAL STUDY. J Biol Chem 291:12862-12870, 2016.

Turner TB, Buchsbaum DJ, Straughn JM Jr, Randall TD, Arend RC. Ovarian cancer and the immune system - The role of targeted therapies.
Gynecol Oncol. 142:349-56, 2016. 
Schultz MJ, Holdbrooks AT, Chakraborty A, Grizzle WE, Landen CN, Buchsbaum DJ, Conner MG, Arend RC, Yoon KJ, Klug CA, Bullard DC, Kesterson RA, Oliver PG, O'Connor AK, Yoder BK, Bellis SL: The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype. Cancer Res 76:3978-3988, 2016.   27216178 
Kirby MK, Ramaker RC, Gertz J, Davis NS, Johnston BE, Oliver PG, Sexton KC, Greeno EW, Christein JD, Heslin MJ, Posey JA, Grizzle WE, Vickers SM, Buchsbaum DJ, Cooper SJ, Myers RM. RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. Mol Oncol. 10:1169-82, 2016.  27282075 
Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ. Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget. 7:86803-86815, 2016  27888804 
McDaniel JM, Varley KE, Gertz J, Savic DS, Roberts BS, Bailey SK, Shevde LA, Ramaker RC, Lasseigne BN, Kirby MK, Newberry KM, Partridge EC, Jones AL, Boone B, Levy SE, Oliver PG, Sexton KC, Grizzle WE, Forero A, Buchsbaum DJ, Cooper SJ, Myers RM. Genomic regulation of invasion by STAT3 in triple negative breast cancer. Oncotarget 8:8226-8238, 2017.  28030809 
Kasten BB, Arend RC, Katre AA, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ: B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl Med Biol 47:23-30, 2017.

Turner TB, Meza-Perez S, Londoño A, Katre A, Peabody JE, Smith HJ, Forero A, Norian LA, Straughn JM Jr, Buchsbaum DJ, Randall TD, Arend RC: Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth. Oncotarget 8:44159-44170, 2017.  28498806 

Immunotherapy, Wnt inhibitors, pancreatic cancer, breast cancer, ovarian cancer